Prestige Consumer Healthcare Inc. (PBH) Moves to Stabilize Eye Care Amid 2025 Headwinds

Core Insights - Prestige Consumer Healthcare Inc. is focusing on growth in its eye care business despite operational challenges in 2025 [1] - The acquisition of Pillar5 Pharma aims to resolve supply constraints and support long-term expansion in the eye care segment [2] - The company reported a 6.6% year-over-year revenue decline in Q1 2026 but showed momentum in other segments, including international OTC healthcare growth [3] Group 1: Company Strategy - Prestige Consumer Healthcare Inc. is taking strategic steps to secure growth in its eye care business amid operational challenges in 2025 [1] - The acquisition of Pillar5 Pharma is intended to address previous supply constraints and ensure reliable production for the Clear Eyes brand [2] Group 2: Financial Performance - The company experienced a 6.6% year-over-year revenue decline in Q1 2026 [3] - Despite the revenue decline, there was momentum in other business segments, including international OTC healthcare growth and improved gross margins [3] Group 3: Leadership Perspective - CEO Ron Lombardi emphasized that integrating Pillar5's capabilities strengthens the Clear Eyes franchise and enhances overall business resilience [3]